°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

World Generic Markets(WGM)

World Generic Markets

¸®¼­Ä¡»ç Fitch Solutions, Inc.
¹ßÇàÁ¤º¸ 12 ȸ/³â »óǰ ÄÚµå 12843
ÆäÀÌÁö Á¤º¸ ¿µ¹® 20 Pages
°¡°Ý
US $ 1,265 £Ü 1,443,000 PDF (Single User License)


World Generic Markets(WGM) World Generic Markets
¹ßÇàÁ¤º¸ : 12 ȸ/³â ÆäÀÌÁö Á¤º¸ : ¿µ¹® 20 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Åë½Å½ÃÀå¿¡ °üÇÑ ¸®¼­Ä¡È¸»ç·Î ±ÇÀ§ ÀÖ´Â Á¤º¸¸¦ Á¦°øÇϰí ÀÖ´Â Espicom Business Intelligence(º»»ç: ¿µ±¹)¿¡¼­´Â ±â¾÷ °æ¿µÁø°ú ºÐ¼®°¡¸¦ ´ë»óÀ¸·Î ÇÑ ¼¼°èÀÇ Á¦³×¸¯ Á¦¾à (ÈĹ߾àǰ)¾÷°èÀÇ ÃֽйßÀüÁ¤º¸¸¦ ´ãÀº ¿ù°£ ´º½º·¹ÅÍ "World Generic Markets"¸¦ ¹ßÇàÇÏ¿´½À´Ï´Ù.

ÃÖ±Ù¿¡´Â ƯÇã°¡ ¸¸·áµÇ´Â ´Ù¼öÀÇ °í¼öÀÍ ÀǾàǰ¿¡ ÀÇÇØ Á¦³×¸¯ ¾àǰ »ê¾÷ÀÇ ¿ªÇÒÀÌ º¯È­ÇÏ¿©, Á¦¾à ºÎ¹®¿¡ À־ ÇÑÃþ ´õ Áß¿äÇÑ ºÎºÐÀ» ´ã´çÇÏ°Ô µÇ¾ú½À´Ï´Ù.

´õ¿íÀÌ °³¹ß½ÃÀåÀÇ °í¼º´É »ý»ê ±â¼úÀÇ ¹ßÀüÀº ¿¬±¸°³¹ß ÁÖüÀÎ Á¦¾à»ç¿Í Á¦³×¸¯ Á¦¾à»ç ¸ðµÎ¿¡°Ô »õ·Î¿î ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

°Ç°­ÀÇ·á¿¡ ´ëÇÑ ¼ÒºñÀÚ¿Í Á¤ºÎÀÇ ÁöÃâ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â ¼Ó¿¡¼­ ¼¼°èÀÇ Á¦³×¸¯ ¾àǰ ºÐ¾ßÀÇ Á¤º¸¿¡ ´ëÇÑ Á¤ÅëÀº Çö¸íÇÑ ÀÏÀÔ´Ï´Ù.

º» ¿ù°£ ´º½º·¹ÅÍ´Â ¸Å¿ù(¿¬°£ 12ȸ) ¾Æ·¡¿Í °°Àº ³»¿ë ±¸¼ºÀ¸·Î ¹ßÇàµÇ¸ç, ¹ßÇàÀÏ¿¡´Â E-MAILÀ» ÅëÇØ ±¸µ¶ÀÚ¿¡°Ô ¾Ë·Áµå¸®°í ÀÖ½À´Ï´Ù.

  • Á¦¾à»ç
  • Á¦Ç°
  • Á¦ÈÞ
  • ƯÇã/¼Ò¼Û
  • °¡°Ý¼³Á¤/ȯ¿ø
  • Á¤ºÎÀÇ Á¤Ã¥
mys 03.04.02

BMI View: This FY13 report shows that final settlement agreements are on an upward trend, but those with potential pay-for-delay implications are currently falling. The report acts as an annual barometer for current legal thinking on the issue; the lack of a clear trend reflects fluctuating legal opinions. The FY14 report will show more fully the impact of the Supreme Court ruling in 2013 on pay-for-delay agreements.

Table of Contents

Editor's Note

  • Despite Overall Upward Trend, FTC Report Shows Fluctuations In Settlement Agreements

Americas

Chile

  • Company News
    • Abbott Completes Acquisition Of CFR

USA

  • Company News
    • Fosun To Invest In Amerigen
    • Actavis Launches US Generic Speciality Injectable Portfolio
  • Patent & Litigation News
    • Helsinn Reaches Palonosetron Settlement With Sandoz
    • Sunovion Files Lurasidone Patent Infringement Lawsuits
    • Actavis Challenges US Abstral Patents
    • Akorn Initiates Difluprednate Patent Challenge
    • Mounting Patent Challenges Will Determine Supernus' Financial Rewards
  • Product Updates
    • Mylan Launches Valsartan In US
    • US Approval Of Sandoz' Filgrastim Advances With Small Steps, Not Giant Leaps
    • Colchicine Marketing Battle To Re-Emerge In US
    • Perrigo Launches Testosterone Gel In US
    • Hospira Files US Epoetin Alfa Biosimilar Application
    • Perrigo Launches Clobetasol Spray In US
    • Jubilant Gains US Mycophenolate And Rizatriptan Approvals
    • Mylan Launches Lamivudine In US
    • Elite Commences Isradipine Shipments
    • Akorn Gains US Phenylephrine Ophthalmic Solution Approval

Europe

UK

  • Regulatory News
    • NICE Updates Biosimilars Guidance

Asia/Pacific

India

  • Patent & Litigation News
    • Gilead Likely To Weather The Indian Sofosbuvir Patent Rejection Storm

Singapore

  • Company News
    • Strides' Singapore Subsidiary Gains International Headquarters Status
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q